Press "Enter" to skip to content

Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian CancerPivotal Trial Expected to be Initiated During 1Q21 – BioSpace

admin 0

Aravive Announces Phase 3 Trial Design for AVB-500 in Platinum Resistant Ovarian CancerPivotal Trial Expected to be Initiated During 1Q21  BioSpace
“ovarian cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *